New study tests powerful cholesterol drug right after heart attacks

NCT ID NCT04951856

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding evolocumab (Repatha) to standard care helps people who recently had a heart attack reach very low LDL cholesterol levels and avoid death or unplanned heart-related hospital stays. About 2,166 participants with STEMI or NSTEMI will be randomly assigned to evolocumab injections every two weeks or usual care. The trial is active but no longer recruiting, and results are expected to show if this approach is better than standard cholesterol management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Evolocumab (Repatha), a cholesterol-lowering injection
What this could lead to
If it works, this could show that adding evolocumab right after a heart attack helps more people reach very low cholesterol goals and reduces the risk of death or heart-related hospital stays.
What could go wrong
This is a phase 4 trial, so the drug is already approved, but it may not prove a clear benefit over standard care. Side effects like injection-site reactions or muscle pain are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ST-ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.